All News
ACR25 - Day 1 Report
ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content.
Read Article
ADA-biosimilar use surged just before CVS formulary change then dropped sharply after. In RISE data, uptake reached 25% of users overall. Formulary policies reshape prescribing, but sustaining adoption needs alignment with patient access and preferences.
@RheumNow #ACR25 A#1042
Jiha Lee JihaRheum ( View Tweet)
Many GLP-1 drugs in the pipeline for management in #OA
#ACR25 @rheumnow https://t.co/y3UCp0CcUb
Bella Mehta bella_mehta ( View Tweet)
#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Open-label MTX vs. Toci in GCA in METOGiA
Wk 78:
37% w/o relapse in MTX arm
46% w/o relapse in Toci arm
MTX was NOT non-inferior to Toci
Toci superior in 2ndary endpoints
Cumulative doses GC not significantly different
#ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Open label noninferiority RCT "METOGiA" in GCA
TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78
Everyone also got pred; are we sure MTX works at all?
@RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7
Links:
Mike Putman EBRheum ( View Tweet)
#ACR25 Abstr#1526 Finally it’s here! Consensus-based guidance on GC #steroid tapering in patients with #SLE. Included considerations before tapering, tapering schedules and monitoring during tapering. Looking forward to the uptake and hearing patients’ views @RheumNow #ACRBest https://t.co/FFl2TFhtTa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls
Without much surprise GLP-1 treated pts had lower risk of MACE and death
Observational, retrospective study.
Now awaiting the prospective evidence.
RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK
Aurelie Najm AurelieRheumo ( View Tweet)
Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube
@alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology:
- bias at scale
- erosion of skills
- data regulatory issues
(for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better)
@RheumNow https://t.co/FyNes40Z7q
David Liew drdavidliew ( View Tweet)
Summary take home points by Dr Highland
1. PAH and PH-ILD are associated with high mortality in patients with SARDs
2. Multimodal and early screening is recommended
3. “It takes a village” work with Pulm and Cardiology colleagues
@RheumNow #ACR2025 https://t.co/Xa7TecMOIe
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed @RheumNow #ACR2025 https://t.co/qazQNk4ovR
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Advantages over autologous/allogenic:
-No apheresis
-No conditioning chemo
-Shorter hospital stays ~3 days
-Ability to redose in partial responder
@RheumNow https://t.co/pbem7A5Iq5
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
2 year extension data from SELECT-GCA:
Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo
Higher rates zoster, CK elevation in UPA group
#ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Social media based outreach to pts for research
Out of 617,207 users engaged, 6 filled the contact form
Based on this social media (knowing also promotion costs) might not be the best strategy to recruit for clinical trials
@RheumNow #ACR25 https://t.co/qCH9WXyTD7
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#803 We need more data to justify biologics before conventional immunosuppressant in #SLE. Post-hoc analysis of 5 Phase 3 RCTs = improved efficacy & GC reduction in BEL+No IS vs PBO+IS. Potential selection bias as control group might be doomed to fail @RheumNow https://t.co/kXmrOUbJzj
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
CE study BEL vs csDMARDs in TriNetX
Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis
Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats
Do you believe it?
#ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP
Links:
Mike Putman EBRheum ( View Tweet)
